In the last trading session, 1.33 million shares of the Akebia Therapeutics Inc (NASDAQ:AKBA) were traded, and its beta was 0.65. Most recently the company’s share price was $1.80, and it changed around $0.01 or 0.56% from the last close, which brings the market valuation of the company to $377.94M. AKBA currently trades at a discount to its 52-week high of $2.48, offering almost -37.78% off that amount. The share price’s 52-week low was $0.80, which indicates that the current value has risen by an impressive 55.56% since then. We note from Akebia Therapeutics Inc’s average daily trading volume that its 10-day average is 2.95 million shares, with the 3-month average coming to 1.82 million.
Akebia Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended AKBA as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Instantly AKBA has showed a green trend with a performance of 0.56% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0000 on recent trading dayincreased the stock’s daily price by 10.0%. The company’s shares are currently up 45.16% year-to-date, but still down -9.55% over the last five days. On the other hand, Akebia Therapeutics Inc (NASDAQ:AKBA) is 34.33% up in the 30-day period. We can see from the shorts that 14.84 million shares have been sold at a short interest cover period of 8.89 day(s).
The consensus price target as assigned by Wall Street analysts is $6.5, which translates to bulls needing to increase their stock price by 72.31% from its current value. Analyst projections state that AKBA is forecast to be at a low of $6 and a high of $7.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
Akebia Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 56.52 percent over the past six months and at a 14.29% annual growth rate that is well below the industry average of 15.60%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.46%.
AKBA Dividends
Akebia Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-12.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.09% of Akebia Therapeutics Inc shares, and 27.29% of them are in the hands of institutional investors. The stock currently has a share float of 27.88%. Akebia Therapeutics Inc stock is held by 140.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.6786% of the shares, which is about 11.64 million shares worth $11.87 million.
VANGUARD GROUP INC, with 4.526% or 9.28 million shares worth $9.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 5.59 shares worth $10.06 million, making up 2.56% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 5.34 shares worth around $9.61 million, which represents about 2.45% of the total shares outstanding.
